Interleukin-6 promoter polymorphism

risk and pathology of Alzheimer's disease

Y Zhang, A Hayes, A Pritchard, U Thaker, M S Haque, H Lemmon, J Harris, A Cumming, J C Lambert, M C Chartier-Harlin, D St Clair, T Iwatsubo, D M Mann, C L Lendon

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Inflammatory and immune responses are involved in the pathogenesis of Alzheimer's disease (AD). Interleukin-6 (IL-6), an inflammatory cytokine, is thought to play a role in neurodegeneration of the central nervous system and has been associated with increased amyloid precursor protein expression in vitro and greater cognitive decline. Previously a C - 174G polymorphism in the promoter of IL-6, which influences expression in vitro, has been found associated in some studies but not all. We investigated this polymorphism in a large independent UK sample of AD cases (n = 356) and controls (n = 434) but found no association. We extended the study to genotype/phenotype correlations but found no correlation with age of onset (it = 338), brain amyloid load (it = 126) or Tau load (17 101), brain microglial cell load (n = 65) or brain reactive astrocytes (n = 127). Our data do not support a pathogenic role in AD for the C 174G polymorphism in isolation. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)99-102
Number of pages4
JournalNeuroscience Letters
Volume362
Issue number2
Early online date16 Apr 2004
DOIs
Publication statusPublished - 20 May 2004

Fingerprint

Interleukin-6
Alzheimer Disease
Pathology
Brain
Amyloid beta-Protein Precursor
Genetic Association Studies
Age of Onset
Amyloid
Astrocytes
Central Nervous System
Cytokines
In Vitro Techniques
Cognitive Dysfunction

Keywords

  • Alzheimer's disease
  • polymorphism
  • interleukin-6
  • promoter
  • brain
  • amyloid load
  • microglial cell load
  • reactive astrocytes
  • genetic polymorphisms
  • association
  • Beta
  • population
  • protein

Cite this

Zhang, Y., Hayes, A., Pritchard, A., Thaker, U., Haque, M. S., Lemmon, H., ... Lendon, C. L. (2004). Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease. Neuroscience Letters, 362(2), 99-102. https://doi.org/10.1016/j.neulet.2004.03.008

Interleukin-6 promoter polymorphism : risk and pathology of Alzheimer's disease. / Zhang, Y ; Hayes, A ; Pritchard, A ; Thaker, U ; Haque, M S ; Lemmon, H ; Harris, J ; Cumming, A ; Lambert, J C ; Chartier-Harlin, M C ; St Clair, D ; Iwatsubo, T ; Mann, D M ; Lendon, C L .

In: Neuroscience Letters, Vol. 362, No. 2, 20.05.2004, p. 99-102.

Research output: Contribution to journalArticle

Zhang, Y, Hayes, A, Pritchard, A, Thaker, U, Haque, MS, Lemmon, H, Harris, J, Cumming, A, Lambert, JC, Chartier-Harlin, MC, St Clair, D, Iwatsubo, T, Mann, DM & Lendon, CL 2004, 'Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease', Neuroscience Letters, vol. 362, no. 2, pp. 99-102. https://doi.org/10.1016/j.neulet.2004.03.008
Zhang Y, Hayes A, Pritchard A, Thaker U, Haque MS, Lemmon H et al. Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease. Neuroscience Letters. 2004 May 20;362(2):99-102. https://doi.org/10.1016/j.neulet.2004.03.008
Zhang, Y ; Hayes, A ; Pritchard, A ; Thaker, U ; Haque, M S ; Lemmon, H ; Harris, J ; Cumming, A ; Lambert, J C ; Chartier-Harlin, M C ; St Clair, D ; Iwatsubo, T ; Mann, D M ; Lendon, C L . / Interleukin-6 promoter polymorphism : risk and pathology of Alzheimer's disease. In: Neuroscience Letters. 2004 ; Vol. 362, No. 2. pp. 99-102.
@article{8f295c09cd46407791e5c5f73ef32037,
title = "Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease",
abstract = "Inflammatory and immune responses are involved in the pathogenesis of Alzheimer's disease (AD). Interleukin-6 (IL-6), an inflammatory cytokine, is thought to play a role in neurodegeneration of the central nervous system and has been associated with increased amyloid precursor protein expression in vitro and greater cognitive decline. Previously a C - 174G polymorphism in the promoter of IL-6, which influences expression in vitro, has been found associated in some studies but not all. We investigated this polymorphism in a large independent UK sample of AD cases (n = 356) and controls (n = 434) but found no association. We extended the study to genotype/phenotype correlations but found no correlation with age of onset (it = 338), brain amyloid load (it = 126) or Tau load (17 101), brain microglial cell load (n = 65) or brain reactive astrocytes (n = 127). Our data do not support a pathogenic role in AD for the C 174G polymorphism in isolation. (C) 2004 Elsevier Ireland Ltd. All rights reserved.",
keywords = "Alzheimer's disease, polymorphism, interleukin-6, promoter, brain, amyloid load, microglial cell load, reactive astrocytes, genetic polymorphisms, association, Beta, population, protein",
author = "Y Zhang and A Hayes and A Pritchard and U Thaker and Haque, {M S} and H Lemmon and J Harris and A Cumming and Lambert, {J C} and Chartier-Harlin, {M C} and {St Clair}, D and T Iwatsubo and Mann, {D M} and Lendon, {C L}",
year = "2004",
month = "5",
day = "20",
doi = "10.1016/j.neulet.2004.03.008",
language = "English",
volume = "362",
pages = "99--102",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Interleukin-6 promoter polymorphism

T2 - risk and pathology of Alzheimer's disease

AU - Zhang, Y

AU - Hayes, A

AU - Pritchard, A

AU - Thaker, U

AU - Haque, M S

AU - Lemmon, H

AU - Harris, J

AU - Cumming, A

AU - Lambert, J C

AU - Chartier-Harlin, M C

AU - St Clair, D

AU - Iwatsubo, T

AU - Mann, D M

AU - Lendon, C L

PY - 2004/5/20

Y1 - 2004/5/20

N2 - Inflammatory and immune responses are involved in the pathogenesis of Alzheimer's disease (AD). Interleukin-6 (IL-6), an inflammatory cytokine, is thought to play a role in neurodegeneration of the central nervous system and has been associated with increased amyloid precursor protein expression in vitro and greater cognitive decline. Previously a C - 174G polymorphism in the promoter of IL-6, which influences expression in vitro, has been found associated in some studies but not all. We investigated this polymorphism in a large independent UK sample of AD cases (n = 356) and controls (n = 434) but found no association. We extended the study to genotype/phenotype correlations but found no correlation with age of onset (it = 338), brain amyloid load (it = 126) or Tau load (17 101), brain microglial cell load (n = 65) or brain reactive astrocytes (n = 127). Our data do not support a pathogenic role in AD for the C 174G polymorphism in isolation. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

AB - Inflammatory and immune responses are involved in the pathogenesis of Alzheimer's disease (AD). Interleukin-6 (IL-6), an inflammatory cytokine, is thought to play a role in neurodegeneration of the central nervous system and has been associated with increased amyloid precursor protein expression in vitro and greater cognitive decline. Previously a C - 174G polymorphism in the promoter of IL-6, which influences expression in vitro, has been found associated in some studies but not all. We investigated this polymorphism in a large independent UK sample of AD cases (n = 356) and controls (n = 434) but found no association. We extended the study to genotype/phenotype correlations but found no correlation with age of onset (it = 338), brain amyloid load (it = 126) or Tau load (17 101), brain microglial cell load (n = 65) or brain reactive astrocytes (n = 127). Our data do not support a pathogenic role in AD for the C 174G polymorphism in isolation. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

KW - Alzheimer's disease

KW - polymorphism

KW - interleukin-6

KW - promoter

KW - brain

KW - amyloid load

KW - microglial cell load

KW - reactive astrocytes

KW - genetic polymorphisms

KW - association

KW - Beta

KW - population

KW - protein

U2 - 10.1016/j.neulet.2004.03.008

DO - 10.1016/j.neulet.2004.03.008

M3 - Article

VL - 362

SP - 99

EP - 102

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 2

ER -